PL1732887T3 - Pochodne 1-(1H-indol-1-ylo)-3-(4-metylopiperazyno-1-ylo)-1-fenylopropan-2-olu i związki pokrewne jako modulatory aktywności norepinefryny (NE) i serotoniny (5-HT) oraz wychwytu zwrotnego monoaminy do leczenia objawów naczynioworuchowych (VMS) - Google Patents

Pochodne 1-(1H-indol-1-ylo)-3-(4-metylopiperazyno-1-ylo)-1-fenylopropan-2-olu i związki pokrewne jako modulatory aktywności norepinefryny (NE) i serotoniny (5-HT) oraz wychwytu zwrotnego monoaminy do leczenia objawów naczynioworuchowych (VMS)

Info

Publication number
PL1732887T3
PL1732887T3 PL05730271T PL05730271T PL1732887T3 PL 1732887 T3 PL1732887 T3 PL 1732887T3 PL 05730271 T PL05730271 T PL 05730271T PL 05730271 T PL05730271 T PL 05730271T PL 1732887 T3 PL1732887 T3 PL 1732887T3
Authority
PL
Poland
Prior art keywords
serotonine
vms
methylpiperazin
norepinephrine
indol
Prior art date
Application number
PL05730271T
Other languages
English (en)
Inventor
Callain Younghee Kim
Paige Erin Mahaney
Eugene John Trybulski
Puwen Zhang
Eugene Anthony Terefenko
Casey Cameron Mccomas
Michael Anthony Marella
Richard Dale Coghlan
Gavin David Heffernan
Stephen Todd Cohn
An Thien Vu
Joseph Peter Sabatucci
Fei Ye
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PL1732887T3 publication Critical patent/PL1732887T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL05730271T 2004-03-30 2005-03-29 Pochodne 1-(1H-indol-1-ylo)-3-(4-metylopiperazyno-1-ylo)-1-fenylopropan-2-olu i związki pokrewne jako modulatory aktywności norepinefryny (NE) i serotoniny (5-HT) oraz wychwytu zwrotnego monoaminy do leczenia objawów naczynioworuchowych (VMS) PL1732887T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US55765104P 2004-03-30 2004-03-30
US56986304P 2004-05-11 2004-05-11
US11/091,885 US7517899B2 (en) 2004-03-30 2005-03-28 Phenylaminopropanol derivatives and methods of their use
EP05730271A EP1732887B1 (en) 2004-03-30 2005-03-29 1-(1h-indol-1-yl)-3-(4-methylpiperazin-1-yl)-1-phenyl propan-2-ol derivatives and related compounds as modulators of the norepinephrine (ne) and the serotonine (5-ht) activity and the monoamine reuptake for the treatment of vasomotor symptoms (vms)
PCT/US2005/010511 WO2005097744A1 (en) 2004-03-30 2005-03-29 1-(1h-indol-1-yl)-3-(4-methylpiperazin-1-yl)-1-phenyl propan-2-ol derivatives and related compounds as modulators of the norepinephrine (ne) and the serotonine (5-ht) activity and the monoamine reuptake for the treatment of vasomotor symptoms (vms)

Publications (1)

Publication Number Publication Date
PL1732887T3 true PL1732887T3 (pl) 2008-05-30

Family

ID=34964018

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05730271T PL1732887T3 (pl) 2004-03-30 2005-03-29 Pochodne 1-(1H-indol-1-ylo)-3-(4-metylopiperazyno-1-ylo)-1-fenylopropan-2-olu i związki pokrewne jako modulatory aktywności norepinefryny (NE) i serotoniny (5-HT) oraz wychwytu zwrotnego monoaminy do leczenia objawów naczynioworuchowych (VMS)

Country Status (20)

Country Link
US (3) US7517899B2 (pl)
EP (1) EP1732887B1 (pl)
JP (1) JP2007531751A (pl)
KR (1) KR20060134186A (pl)
AR (1) AR048675A1 (pl)
AT (1) ATE383337T1 (pl)
AU (1) AU2005230900A1 (pl)
BR (1) BRPI0509390A (pl)
CA (1) CA2560967A1 (pl)
CR (1) CR8639A (pl)
DE (1) DE602005004268T2 (pl)
DK (1) DK1732887T3 (pl)
EC (1) ECSP066899A (pl)
ES (1) ES2299025T3 (pl)
IL (1) IL178185A0 (pl)
NO (1) NO20064892L (pl)
PE (1) PE20060288A1 (pl)
PL (1) PL1732887T3 (pl)
TW (1) TW200536532A (pl)
WO (1) WO2005097744A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7414052B2 (en) * 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
ES2340180T3 (es) * 2004-06-01 2010-05-31 F.Hoffmann-La Roche Ag 3-amino-1-arilpropil-indoles como inhibidores de reabsorcion de monoaminas.
AU2006242542A1 (en) * 2005-04-29 2006-11-09 Wyeth Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles
CA2623423A1 (en) * 2005-09-29 2007-04-12 Wyeth Substituted propylamine derivatives and methods of their use
WO2007041023A1 (en) * 2005-09-29 2007-04-12 Wyeth 1- (1h- indol- 1-yl) -3- (methylamino) -1- phenylpropan-2-ol derivatives and related compounds as modulators of the monoamine reuptake for the treatment of vasomotor symptoms (vms)
CA2629962A1 (en) * 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag 3-amino-1-arylpropyl indoles and aza-substituted indoles
KR20080080593A (ko) 2005-11-30 2008-09-04 에프. 호프만-라 로슈 아게 3-아미노-1-아릴프로필 인돌의 합성 방법
ATE442368T1 (de) * 2005-11-30 2009-09-15 Hoffmann La Roche 3-amino-2-arylpropylazaindole und anwendungen davon
CL2007002449A1 (es) * 2006-08-24 2008-03-07 Wyeth Corp Compuestos derivados de indolinona fenilaminopropanol; composicion farmaceutica; procedimiento de preparacion de dichos compuestos, utiles en disfuncion sexual, trastornos gastrointestinales y genitourinarios, fibromialgia, fatiga cronica, trastornos
WO2008042362A1 (en) * 2006-10-04 2008-04-10 Wyeth Arylamino-arylpropanolamine derivatives and methods of their use
HUP1000598A2 (en) 2010-11-05 2012-09-28 Richter Gedeon Nyrt Indole derivatives
CN103384661B (zh) * 2011-01-20 2016-08-10 默沙东公司 盐皮质激素受体拮抗剂
AR091770A1 (es) 2012-07-17 2015-02-25 Glaxosmithkline Intellectual Property N 2 Ltd Indolcarbonitrilos moduladores selectivos de receptores androgenicos
KR101460738B1 (ko) * 2012-08-23 2014-11-12 한국과학기술연구원 신규한 2-나프틸 프로판-2-올 화합물, 이를 포함하는 약학 조성물, 및 상기 약학 조성물을 포함하는 제제
MX2021000043A (es) 2018-07-03 2021-03-25 Univ Illinois Activadores de la respuesta a proteinas desplegadas.
US20220296604A1 (en) * 2019-08-08 2022-09-22 New York University Indole compounds as modulators of rage activity and uses thereof
CN114539080A (zh) * 2022-03-02 2022-05-27 八叶草健康产业研究院(厦门)有限公司 一种2-(2-氨基-6-氯苯基)-乙酸钠的制备方法

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3454554A (en) * 1960-10-14 1969-07-08 Colgate Palmolive Co Aminoalkyliminodibenzyl compounds
US4123543A (en) * 1971-09-16 1978-10-31 Ab Kabi Derivatives of substituted indoline lactans with effect on the central nervous system
CS175831B1 (pl) 1974-12-17 1977-05-31
IL56369A (en) * 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4310524A (en) * 1980-04-11 1982-01-12 Richardson-Merrell, Inc. TCA Composition and method for rapid onset antidepressant therapy
PH18686A (en) 1981-05-26 1985-08-29 Merck & Co Inc 1-(3 halo-2-pyridinyl) piperazine
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
EP0135905A3 (de) 1983-09-29 1986-10-22 ASTA Pharma Aktiengesellschaft Neue 1-(Alkyl-hydroxy-phenyl)-1-hydroxy-2-(alkylamino)-propane
CA1280421C (en) 1985-07-02 1991-02-19 Albert A. Carr 1,4-disubstituted piperidinyl derivatives
ZA885824B (en) 1987-08-14 1989-04-26 Merrell Dow Pharma Novel antidepressants
US4826844A (en) * 1987-09-30 1989-05-02 American Home Products Corporation Substituted 1-(aralkyl-piperazinoalkyl) cycloalkanols
CA2083698C (en) 1990-06-01 1997-11-04 Albert A. Carr (+)-alpha-(2,3-dimethoxyphenyl)-1- [2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
US5648511A (en) * 1990-11-19 1997-07-15 G.D. Searle & Co. Method for making intermediates useful in the synthesis of retroviral protease inhibitors
FR2686878B1 (fr) 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
FR2708605A1 (fr) 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5502047A (en) * 1993-03-22 1996-03-26 Kavey; Neil B. Treatment for insomnia
US5516774A (en) * 1993-07-29 1996-05-14 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
FR2708606B1 (fr) 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
FR2714378B1 (fr) 1993-12-24 1996-03-15 Sanofi Sa Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
AU3414295A (en) 1994-08-19 1996-03-14 Nps Pharmaceuticals, Inc. Methods and compounds active at metabotropic glutamate receptors useful for treatment of neurological disorders and diseases
AU5857296A (en) 1995-05-17 1996-11-29 Eli Lilly And Company Use of leukotriene antagonists for alzheimer's disease
FR2740136B1 (fr) 1995-10-24 1998-01-09 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
GB9606016D0 (en) * 1996-03-22 1996-05-22 Smithkline Beecham Plc Novel use
EA000976B1 (ru) 1996-03-25 2000-08-28 Эли Лилли Энд Компани Композиция для снятия боли и способ снятия боли
WO1998014208A1 (en) 1996-09-30 1998-04-09 President And Fellows Of Harvard College Reactive ligands and covalent ligand-protein complexes
FR2757157B1 (fr) 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
IL138084A0 (en) 1998-03-02 2001-10-31 Lilly Co Eli Fluoxetine hydrochloride for decreasing hot flashes
TW528754B (en) 1998-04-29 2003-04-21 Wyeth Corp Indolyl derivatibes as serotonergic agents
CA2336962A1 (en) 1998-07-13 2000-01-20 Alan Mueller Methods and compounds for treating depression and other disorders
CA2368083A1 (en) 1999-04-06 2000-10-12 Sepracor Inc. Derivatives of venlafaxine and methods of preparing and using the same
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
EA011094B1 (ru) 1999-07-01 2008-12-30 Фармация Энд Апджон Компани Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
FR2804114B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2804115B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
AU2001249397A1 (en) 2000-03-24 2001-10-08 Cor Therapeutics, Inc. Oxindole inhibitors of factor xa
US20030008860A1 (en) * 2002-05-09 2003-01-09 Bakker-Arkema Rebecca Guggemos Treatment of congestive heart failure
GB2362826A (en) 2000-06-02 2001-12-05 Lilly Co Eli A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
JP2004509103A (ja) 2000-09-11 2004-03-25 セプレイコー　インコーポレイテッド モノアミン受容体及び輸送体のリガンドならびにその使用方法
CA2666611A1 (en) 2001-02-12 2002-08-22 Wyeth Novel succinate salt of o-desmethyl-venlafaxine
WO2002078691A1 (en) 2001-03-29 2002-10-10 Eli Lilly And Company Duloxetine for treatment of hot flashes
EP1266659A1 (en) 2001-06-11 2002-12-18 Pantarhei Bioscience B.V. Pyridoxal in combination with serotonin re-uptake inhibitor for the treatment of hot flushes
WO2003010169A1 (en) 2001-07-25 2003-02-06 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 7, 8-dihydro-6h-5-oxa-1-aza-phenanthrene
WO2004089942A2 (en) 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
WO2003037334A1 (en) 2001-10-31 2003-05-08 Merck & Co., Inc. Method for treating or preventing symptoms of hormonal variation including hot flashes
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
EP1485078B1 (en) 2002-03-15 2012-09-26 Cypress Bioscience, Inc. Milnacipran for the treatment of irritable bowel syndrome
TW200402289A (en) * 2002-05-17 2004-02-16 Wyeth Corp Methods of treating gastrointestinary and genitourinary pain disorders
NZ537521A (en) 2002-08-14 2007-05-31 Pharmacia & Upjohn Co Llc Use of reboxetine for the treatment of hot flashes
US20040180879A1 (en) * 2002-10-15 2004-09-16 Deecher Darlene Coleman Novel method of treating vasomotor symptoms
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US7345096B2 (en) * 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20050130987A1 (en) * 2003-10-14 2005-06-16 Wyeth Methods of treating vasomotor symptoms
US7524846B2 (en) * 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7491723B2 (en) * 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
US7550485B2 (en) * 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
US7365076B2 (en) * 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US7419980B2 (en) * 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US7531543B2 (en) * 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
US20050165082A1 (en) * 2003-12-16 2005-07-28 Wyeth Methods of treating vasomotor symptoms
US7414052B2 (en) * 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use

Also Published As

Publication number Publication date
DE602005004268T2 (de) 2009-01-02
US20090093469A1 (en) 2009-04-09
WO2005097744A1 (en) 2005-10-20
ECSP066899A (es) 2006-11-24
DK1732887T3 (da) 2008-04-28
EP1732887A1 (en) 2006-12-20
EP1732887B1 (en) 2008-01-09
BRPI0509390A (pt) 2007-09-18
PE20060288A1 (es) 2006-05-23
DE602005004268D1 (de) 2008-02-21
US20090099164A1 (en) 2009-04-16
CA2560967A1 (en) 2005-10-20
JP2007531751A (ja) 2007-11-08
AU2005230900A1 (en) 2005-10-20
ATE383337T1 (de) 2008-01-15
AR048675A1 (es) 2006-05-17
CR8639A (es) 2007-06-08
ES2299025T3 (es) 2008-05-16
US7517899B2 (en) 2009-04-14
US20050222148A1 (en) 2005-10-06
KR20060134186A (ko) 2006-12-27
NO20064892L (no) 2006-12-13
TW200536532A (en) 2005-11-16
IL178185A0 (en) 2006-12-31

Similar Documents

Publication Publication Date Title
IL178185A0 (en) 1-(1h-indol-1-yl)-3-(4-methylpiperazin-1-yl)-1-phenyl propan-2-ol derivatives and related compounds as modulators of the norepinephrine (ne) and the serotonine (5-ht) activity and the monoamine reuptake for the treatment of vasomotor symptoms (vms)
NO343929B3 (no) 1-[2-(2,4-dimetylfenylsulfanyl-fenyl]-piperazin som en forbindelse med kombinert serotoninreopptak, 5-HT3- og 5HT1A-aktivitet for behandlingen av kognitiv smerte
PL1833799T3 (pl) 3-Fenylo-pirazolowe pochodne jako modulatory 5-HT2A receptora serotoniny użyteczne w leczeniu zaburzeń związanych z tym receptorem
ATE368639T1 (de) Kristalline formen von (-)-(1r,2r)-3-(3- dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid
NO20083057L (no) Sulfonyl substituerte 1H-indoler som ligander til 5-hydroksytryptamin reseptorer
WO2005121065A3 (en) DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS
MY155036A (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
AU2006336504A8 (en) 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
HK1121448A1 (en) Primary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto 5-th2a
EP2368871B8 (en) Process for the preparation of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol
TW200716517A (en) Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles
EP1746985A4 (en) METHOD FOR INCREASING THE EFFECT OF SEROTONINE RECOVERY INHIBITORS
DK2407451T3 (da) N,N-substituerede 3-aminopyrrolidin-forbindelser anvendelige som monoamin-genoptagelseshæmmere
NO341679B1 (no) Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren
WO2010120695A3 (en) 5-ht4 receptor agonist compounds for treatment of cognitive disorders
IL174472A0 (en) 1-2'(1,4'-biperidin-1'-yl)-1-(phenyl)-ethyl cyclohexanol derivatives as monoamine reuptake modulators for the treatment of visomotor symptoms
EA200801414A1 (ru) Кальцилитические соединения
WO2010011811A3 (en) 3-(phenoxyphenylmethyl)pyrrolidine compounds
NO20080750L (no) (Indol-3-YL)-heterocykelderivater som agonister av cannabinoid CB1 reseptor
ZA200608134B (en) 1-(1H-indol-1-yl)-3-(4-methylpiperazin-1-yl)-1-phenyl propan-2-ol derivatives and related compounds as modulators of the norepinephrine (NE) and the serotonine (5-HT) activity and the monoamine reuptake for the treatment of vasomotor symptoms (VMS)
IL182738A0 (en) Enantiomers of 3-heteroaryl-8h-8-azabicyclo(3.2.1)oct-2-ene and their use as monoamine neurotransmitter re-uptake inhibitors
WO2004052858A3 (en) Inhibitors of monoamine uptake
NO20073702L (no) Ikke-steroid glukocorticoid reseptor modulatorer
WO2011008572A3 (en) 5-ht3 receptor modulators, methods of making, and use thereof
WO2006122012A3 (en) Polymorphic forms of (s)- tetrahydrofuran-3-yl-3-(3-(3-methoxy-4-(oxazol-5-yl) phenyl) ureido) benzylcarbamate